Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“Breaking: Rick Pazdur to retire from FDA.
I interacted many times over the last 20 plus years with Dr. Pazdur. His leadership and his wisdom helped the field of oncology, and particularly my field, multiple myeloma immensely. We will miss working with him. Wishing him the best in retirement. Kudos!
With Dr. Pazdur in 2019. We received the Giants of Cancer Care honor that year.
An incredible day for me. I’m sad that he is leaving the FDA.
Personally the last 15 years of research that I pursued in smoldering myeloma was inspired by one statement he made to me at a meeting. I never forgot it. I can’t quote the statement. But in essence he said to stop trying to think like a regulator but to be brave and focus on the best trial design for the field and for patients. The rest will follow. And so it did.”
You Can Read: Dr. Richard Pazdur: 25 Years of Transforming Oncology Drug Development at the FDA
You Can Also Watch OncoDaily’s Interview with Dr. Pazdur.